← Leaderboards
Steven Russell Barthel
Brigham And Women'S Hospital
$2,531,097
Attributed
$4,945,249
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,945,249 · 3
By mechanism
R01$4,828,305 · 2
F32$116,944 · 1
Top collaborators
- Tobias Schatton9 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Charles J Dimitroff$9,730,798
- John P Forman$11,830,902
- Francis W. Luscinskas$14,265,022
- Vijay K Kuchroo$71,617,613
- Tanya N. Mayadas$28,624,599
Others in their field
Top investigators on “Blocking Antibodies”
- Paul S. Aisen · Cognition Therapeutics, Inc.$49,917,170
- Sean P. J. Whelan · Washington University$32,424,356
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$26,234,170
- Joren C Madsen · Massachusetts General Hospital$24,269,261
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$21,056,995
- Wanda Phipatanakul · Boston Children'S Hospital$21,005,199
Research focus
Blocking AntibodiesCancer CellCellsRna InterferenceNeoplastic CellMalignant NeoplasmsNeoplasm MetastasisLigandsMediatingModalityMass Spectrum AnalysisImmuneLectinMetastatic MelanomaPathway InteractionsMacrophageMelanomaGlycosylationCell LineageGrowthEpitopesAntibodiesGlycoproteinsMelanoma Cell
Grant awards (11)
Cell type-directed Tim-3 targeting in melanoma$580,109
R01 · FY2025 · CA · contact PI
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$511,820
R01 · FY2025 · CA
Cell type-directed Tim-3 targeting in melanoma$551,025
R01 · FY2024 · CA · contact PI
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$486,230
R01 · FY2024 · CA
Cell type-directed Tim-3 targeting in melanoma$572,297
R01 · FY2023 · CA · contact PI
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$501,583
R01 · FY2023 · CA
Cell type-directed Tim-3 targeting in melanoma$592,227
R01 · FY2022 · CA · contact PI
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$508,408
R01 · FY2022 · CA
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$524,606
R01 · FY2021 · CA
Modeling PCa Bone Metastasis: Dual Role of E-selectin Ligands and Integrins$60,434
F32 · FY2012 · CA · contact PI
Modeling PCa Bone Metastasis: Dual Role of E-selectin Ligands and Integrins$56,510
F32 · FY2010 · CA · contact PI